[STUDY_ID_REMOVED]  
 
   
Study ID:  ITI- 007 -502  
   
Title: 
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the  
         Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of  
         Patients with Major Depressive Disorder  
  
 
 
Original Protocol  Date: 18 Aug  2021  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 1 A Randomized, Double -Blind, Placebo -controlled Multi center Study to A ssess the 
Efficacy  and Safety of Lumateperone as Adjunctive  Therapy in  the Treatment of 
Patients with  Major Depressive Disorder  
Protocol Number:  ITI-007-502 
Original Protocol Date:  18 Aug 2021  
Compound:  Lumateperone  
Study Phase:  3 
Sponsor:  
Confidentiality Statement  
The confidential information in this document is provided to you as an Investigator for review by [CONTACT_10825], your 
staff, and the applicable Institutional Review Board/Independent Ethics Committee. Acceptance of this 
document constitutes agreement that the information contained herein will not be disclosed to others without 
written authorization from Intra- Cellular Therapi[INVESTIGATOR_014], Inc. (ITI), the Sponsor. All financial and nonfinancial 
support for this study will be provided by [CONTACT_1034]. The concepts and information contained in this 
document or generated during the study are considered proprietary and may not be disclosed in whole or in part without the expressed, written consent of ITI.  
This study will be carried out in accordance with ICH GCP, US Code of Federal Regulations applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part  812), 
and all applicable local regulations.  
 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 2 PROTOCOL APPROVAL —SPONSOR SIGNATORIES  
Protocol Title:  A Randomized, Do uble-blind, Placebo -controlled 
Multic enter Study to Assess the Efficacy  and Safety of 
Lumateperone as Adjunctive Therapy in the Treatment of 
Patients with Major Depressive Disorder 
Protocol Number:  ITI-007-502 
Original Protocol Date:  18 Aug  2021  
DocuSign Envelope ID: 6C30FCB4-7EE9-4B63-948D-8588BBA0C803

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 3 TABLE OF CONTENTS  
PROTOCOL APPROVAL —SPONSOR SIGNATORIES  ............................................................ [ADDRESS_1063906] of the Study ......................................................................................... 16  
2.3 Patient Information and Informed Consent .................................................................... 16  
3 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE  ............................. 17  
4 INTRODUCTION  .................................................................................................................. 18  
5 STUDY OBJECTIVES  ........................................................................................................... 21  
5.1 Efficacy Objectives  ........................................................................................................ 21  
5.1.1  Primary Objective  ....................................................................................................... 21  
5.1.2  Key Secondary Efficacy Objective  ............................................................................. 23  
5.1.3  Additional Efficacy Objectives  .................................................................................. 23  
5.2 Safety Objectives ............................................................................................................ 24  
6 INVESTIGATIONAL PLAN  ................................................................................................. 25  
6.1 Overall Study Design and Plan ...................................................................................... 25  
6.2 Scientific Rationale for Study Design  ............................................................................ 26  
6.2.1  Study Design............................................................................................................... 26  
6.2.2  Separate Open -label Safety Study  .............................................................................. 27  
6.2.3  Dose Selection  ............................................................................................................ 27  
6.3 Study Population ............................................................................................................ 27  
6.3.1  Inclusion Criteria  ........................................................................................................ 27  
6.3.2  Exclusion Criteria  ....................................................................................................... 29  
6.4 Stoppi[INVESTIGATOR_2121]  ............................................................................................................ 32  
6.4.1  Discontinuation of Patients from Therapy or Assessment: Patient-level Stoppi[INVESTIGATOR_134248]  [ADDRESS_1063907] of the Study ............................................................................. 34  
7 STUDY TREATMENTS  ........................................................................................................ 35  
7.1 Treatment Administered  ................................................................................................. 35  
7.2 Supply, Storage, and Accountability of Study Treatment .............................................. 36  
7.2.1  Storage of Study Treatment ........................................................................................ 36  
7.2.2  Study Treatment Accountability  ................................................................................. 36  
7.3 Method of Assigning Patients to Treatment Groups ...................................................... 36  
7.4 Blinding .......................................................................................................................... 37  
7.5 Unblinding ...................................................................................................................... 37  
7.6 Monitoring Treatment Compliance ................................................................................ 37  
7.7 Prior and Concomitant Medications ............................................................................... 38  
7.7.1  Prior Medications ....................................................................................................... 38  
7.7.2  Prohibited Medications ............................................................................................... 38  
7.7.3  Rescue Medication  ..................................................................................................... 38  
7.8 Treatment After Discontinuation  ................................................................................... 39  
8 EFFICACY, SAFETY AND OTHER ASSESSMENTS  ....................................................... 40  
8.1 Diagnostic and Other Screening Period Assessments .................................................... 40  
8.1.1  MINI International Neuropsychiatric Interview  ......................................................... 40  
8.1.2  MGH Antidepressant Treatment Response Questionnaire (ATRQ) .......................... 40  
8.1.3  Medical Hi story and Other Information ..................................................................... 40  
8.1.4  Eligibility Review Process .......................................................................................... 40  
8.1.5  Patient Placebo Questionnaire and Training .............................................................. 40  
8.1.6  Quick Inventory for Depressive Symptomatology- Self Report (QIDS -SR-16) ......... 41  
8.2 Efficacy Assessments  ..................................................................................................... 41  
8.2.1  Montgomery-Åsberg Depression Rating Scale (MADRS) ........................................ 41  
8.2.2  Clinical Global Impression -Severity (CGI -S) ............................................................ 41  
8.2.3  Changes in Sexual Functioning Questionnaire ........................................................... 41  
8.3 Safety  .............................................................................................................................. 42  
8.3.1  Adverse Events  ........................................................................................................... 42  
8.3.2  Potent ial Hy’s Law Cases  ........................................................................................... 45  
8.3.3  Pregnancy  ................................................................................................................... 46  
8.3.4  Clinical Laboratory Determinations  ........................................................................... 47  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 5 8.3.5  Vital Signs  .................................................................................................................. 48  
8.3.6  Electrocardiograms  ..................................................................................................... 49  
8.3.7  Columbia–S uicide Severity Rating Scale (C -SSRS)  .................................................. 49  
8.3.8  Extrapyramidal Scales  ................................................................................................ 50  
8.3.9  Modified Physical Examination ................................................................................. 50  
8.4 Pharmacokinetic Assessments ........................................................................................ 51  
8.5 Schedule of Assessments  ............................................................................................... 51  
8.5.1  Screening  .................................................................................................................... 51  
8.5.2  Double- blind Treatment Period (Visit 2 -8/Weeks 0 -6) .............................................. 52  
8.5.3  Safety Follow- up Visit (Visit 9/Day 50 ±3) ............................................................... 55  
9 STATISTICAL METHODS  ................................................................................................... 56  
9.1 General Considerations .................................................................................................. 56  
9.2 Determination of Sample Size ........................................................................................ 56  
9.3 Analysis Populations ...................................................................................................... 56  
9.4 Statistical Analyses  ........................................................................................................ 57  
9.4.1  Patient Disposition  ...................................................................................................... 57  
9.4.2  Demographics and Other Baseline Characteristics  .................................................... 57  
9.4.3  Prior and Concomitant Medication ............................................................................. 57  
9.4.4  Extent of Exposure and Treatment Compliance ......................................................... 58  
9.4.5  Efficacy Analyses  ....................................................................................................... 58  
9.4.6  Multiple Comparisons/Multiplicity  ............................................................................ [ADDRESS_1063908] OF TABLES  
Table 1 -1: Schedule of Evaluations .............................................................................................. 14 
Table 5 -1: Primary Estimand and Intercurrent Events—Hypothetical Strategy  .......................... 21 
Table 7 -1: Study Treatment Dosage and Composition ................................................................. 35 
Table 7 -2: Weekly Study Treatment Cards .................................................................................. 36 
Table 9 -1: Primary Estimand and Intercurrent Events—Hypothetical Strategy  .......................... 59 
Table 9 -2: Supportive Estimand and Intercurrent Events —Treatment Policy Strategy Eliminating 
New ADT Effect  ........................................................................................................................... 60 
Table 9 -3: Additional Estimand and Intercurrent Events —Treatment Policy Strategy Including 
Possible New ADT Effect  ............................................................................................................. 61 
Table 9 -4: Key Secondary Estimand and Intercurrent Events—Hypothetical Strategy  ............... [ADDRESS_1063909] OF FIGURES  
Figure 6-1: Schematic of Study Design  ........................................................................................ [ADDRESS_1063910]  aspartate aminotransferase 
ATRQ Antidepressant Treatment Response Questionnaire 
BMI  body mass index 
BP blood pressure 
bpm beats per minute  
CFR  Code of Federal Regulations 
C-SSRS  Columbia–Suicide Severity Rating Scale 
CGI-BP-S Clinical Global Impression Scale, Bipolar version, 
 Severity  
CRO  Contract research organization  
CSFQ  Changes in Sexual Functioning Questionnaire 
CSR  Clinical study report 
D2 dopamine [ADDRESS_1063911] of 
 1996 
HIV human immunodeficiency virus 
ICE intercurrent event  
ICF informed consent form 
ICH International Council on Harmonisation of Technical 
 Requirements for Registration of Pharmaceuticals for 
 Human Use  
IEC International Ethics Committee  
IND Investigational New Drug (application) 
ITI Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  
ITT intent- to-treat 
IWRS  interactive web response system  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063912] Model for Repeated Measures  
msec millisecond  
PCS potentially clinically significant 
PEER  Pre-Enrollment Eligibility  Review  
PET positron emission tomography 
PK  pharmacokinetic 
PMM  pattern -mixture model 
QIDS -SR-16 Quick Inventory of Depressive Symptomatology-S elf 
 Report-16 item 
QTc QT interval corrected for heart rate  
QTcB  QT interval corrected for heart rate using the Bazett 
 formula (QTcB  = QT/<RR>½) 
QTcF  QT interval corrected for heart rate using the 
 Fridericia formula (QTcF  = QT/<RR>⅓) 
SAE  serious adverse event  
SAS Simpson Angus Scale 
SAP  statistical analysis plan  
SERT serotonin transporter 
SOC  system organ class  
TEAE treatment -emergent adverse event  
UDS  urine drug screen 
ULN  upper limit of normal 
US [LOCATION_002]  
 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 10 1 PROTOCOL SYNOPSIS AND SCHEDULE OF EVALUATIONS  
CLINICAL STUDY SYNOPSIS: Study ITI-007-502 
Title of Study  A Randomized , Double -blind, Placebo -controlled Multicenter Study  to 
Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy  in 
the Treatment of Patients with Major Depressive Disorder . 
Study Centers (Country)  Approximately 60 study centers ([LOCATION_002] and globally).  
Development Phase  3 
Objectives  Primary  Objective  
• To evaluate the efficacy  of lumateperone  42 mg administered once 
daily  compared  with placebo as adjunctive  treatment  to 
antidepressant therapy  in patients with Major Depressive  Disorder  
(MDD)  who have an inadequate response to ongoing antidepressant 
therapy  (ADT)  as measured by [CONTACT_774675] D ay 43  in the 
Montgomery-Å sberg Depression Rating Scale (MADRS)  total score . 
Key Secondary Efficacy Objective 
• To evaluate the efficacy of lumateperone [ADDRESS_1063913] an inadequate response to ongoing 
ADT as measured by [CONTACT_774675] D ay 43 in the Clinical 
Global Impression Scale- Severity (CGI -S). 
Study Design  This is an i nternational, multicenter, randomized, double -blind, placebo -
controlled, parallel- group, fixed- dose study in patients with a primary 
diagnosis of MDD  according to criteria of the Diagnostic  and Statistical 
Manual of Mental Disorders, Fifth Edition  (DSM -5) who have an inadequate 
response to ongoing ADT.  
The study will be conducted in three periods:   
• Screening Period  (up to 2 weeks)  during which patient eligibility 
will be assessed ; 
• Double -blind Treatment Period  (6 week s) in which all patients 
will be randomized to receive placebo or lumateperone 42  mg/day 
in 1:1 ratio.  
• Safety Follow -up Period (1 week) in which all patients will return 
to the clinic for a safety follow -up visit approximately one week 
after the last dose of study treatment.  
Number of Patients  Approximately 470 patients  (235 per trea tment group)  are planned to be  
enroll ed in the Double -blind  Treatment Period . 
Diagnosis and Main Criteria for 
Inclusion and Exclusion  Main Inclusion Criteria  
Patients will be eligible for study participation if they meet the following inclusion criteria:  
1. Provide s written informed consent; 
2. 
Male or female patients between the ages of 18 and 65 years, 
inclusive ;  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 11 3. Meets DSM -5 criteria  for MDD (MDD with psychotic features will 
be acceptable)  as confirmed by [CONTACT_9304] -
approved rater using the MINI  and meet s all of the following 
criteria : 
a. The start of the current  major depressi ve epi[INVESTIGATOR_1865]  (MDE ) is at 
least 8 weeks but not more than 18 months prior to Screening 
(Visit 1) ; 
b. Has at least moderate severity of illness based on rater-
administered MADRS total score ≥  24 at Screen ing (Visit 1)  
and at Baseline (Visit 2); 
c. Has at least moderate severity of illness based on CGI -S score 
≥ 4 at Screen ing (Visit 1)  and at Baseline (Visit 2) ;  
d. Has a Quick Inventory of Depressive Symptom atology -Self 
Report -16 item (QIDS- SR-16) score ≥ 14 at Screen ing 
(Visit 1) and at Baseline (Visit 2);  
e. Has sufficient history and medical record confirmation 
verifying the ADT and the current MDE is causing clinically 
significant distress or impairment in social, occupational, or 
other important areas of functioning.  
4.  Currently having an inadequate response to ADT (less than 50% 
improvement) as confirmed by [CONTACT_143468]  (ATRQ ) and 
taking at least the minimum effective dose (per package insert) of 
one of the following antidepressants as monotherapy treatment for at least 6 weeks duration: 
a. citalopram/escitalopram  
b. fluoxetine  
c. paroxetine  
d. sertraline  
e. duloxetine  
f. levomilnacipran/milnacipran (if locally approved for MDD ) 
g. venlafaxine/desvenlafaxine  
h. bupropi[INVESTIGATOR_2394]  
i. vilazodone  
j. vortioxetine  
All Inclusion Criteria are presented in Section 6.3.1. 
Main Exclusion Criteria  
Patients who meet  any of the following exclusion criteria  will not be able 
to participate in the study : 
1. Within the patient’s lifetime, has a c onfirmed DSM -5 psychiatric 
diagnosis other than MDD, including : 
a. Schizophrenia,  Schizoaffective D isorder, Schizophreniform 
Disorder or other psychot ic disorder ; 
b. Bipolar Disorder;  
2. Within 6  months of Screening , has a confirmed DSM- 5 psychiatric 
diagnosis other than MDD including: 
a. Anxiety disorders such as Panic Disorder  or Generalized 
Anxiety Disorder ; Obsessive -compulsive Disorder; 
Posttraumatic Stress Disorder as primary diagnoses. Note: 
Anxiety symptoms may be allowed if secondary to MDD, 
provided these symptoms do not require con current treatment;  
b. Eating disorder;  
c. Substance use disorder s (excluding  nicotine) ; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 20 21 
Confidential  Page 13 Statistical Methods  The primary efficacy endpoint  will be change from Baseline to Day 43  in 
MADRS total score. Based on the primary hypothetical estimand strategy 
which assumes patients are on study treatment up to the primary time point (Day 43), efficacy data collected after discontinuation of study treatment (ie, efficacy assessment performed more than [ADDRESS_1063914] dose of study 
treatment) and/or after starting new ADT will be set to missing and will not 
be included in the primary analysis. Instead, these missing data will be 
assumed as missing at random. The primary a nalysis to estimate and compare 
the treatment effects of lumateperone vs placebo as defined by [CONTACT_143469] a mixed-
effects model for repeated 
measures (MMRM) with change from baseline at each study visit as the 
response var iable, and treatment group, study site (or pooled site)  and stud y 
visit as factors , baseline MADRS total score as covariate, and interaction 
terms for baseline MADRS total score- by-study visit and treatment group -
by-study visit. An unstructured covariance matrix will be used to model  the 
covariance of within -patient scores. The Kenward -Roger approximation will 
be used to estimate the denominator degrees of freedom. Treatment 
difference will be estimated via contrast based on treatment group and 
treatment gr oup-by-study visit factors.  
The key secondary efficacy parameter will be the change from baseline to 
Day [ADDRESS_1063915] at the 2- sided 0.05 level, 
and if significant, the key secondary endpoint will be tested at the 2- sided 
0.05 level.  
Primary e fficacy analyses will be based on the modified Intent -to-Treat 
(mITT) Population, defined as all randomized patients who received at least 
[ADDRESS_1063916] -baseline , on-treatment  
assessment of the MADRS total score (on-treatment MADRS assessment s 
are those performed no later than [ADDRESS_1063917] dose of study 
treatment) . 
Key se condary efficacy analyses will also be based on the mITT Population. 
An estimation and comparison of the treatment effects of lumateperone vs 
placebo for the key secondary endpoint are based on the hypothetical 
estimand (similar to that defined for the primary analysis, using assessed CGI-S score up to [ADDRESS_1063918] study dose and not including those 
assessed after new ADT).  
All safety parameters will be summarized descriptively. Safety analyses will be based on the Safety Population defined as all randomized patients who 
received at least one dose of investigational product.  
Individual plasma concentrations will be listed and summarized by [CONTACT_765] . 
Plasma concentrations will be analyzed using a population PK approach. The results from the population PK a nalyses  will be presented in a separate 
report.  
Approximately 470 patients will be randomly assigned to  1 of the 2 treatment 
groups  (lumateperone 42  mg or matching placebo). Assuming a common 
drop- out rate of 20% and a common correlation of 0.7  between the repeated 
measures , the sample size of 235 patients per treatment group will provide 
approximately 90% statistical power for the effect size of 0.33 (treatment difference of 3.[ADDRESS_1063919] deviation of 10) for the 
primary effica cy endpoint.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063920] (IRB) and Independent  Ethics Committee (IEC) is 
required before the start of the study. A copy of the approval letter will be supplied to Intra -Cellular 
Therapi[INVESTIGATOR_014], Inc. (the Sponsor) or its designee along with a roster of IRB/IEC members. During the 
course of the study, the Investigator will provide timely and accurate reports to the IRB/IEC on the progress of the study, at intervals not exceeding 1 year (or as appropriate) and will notify the IRB/IEC of serious adverse events (SAEs) or other significant safety findings. The study protocol, informed consent form (ICF), information sheet advertisements, and amendments (if any) will be approved by [CONTACT_1026]/IECs at the study centers in conformance with US CFR, Title  21, Part  [ADDRESS_1063921] their 
origins in the Declaration of Helsinki. This clinical study will comply with the ICH Guidance on General Considerations for Clinical Trials (ICH -E8; 62 FR  [ZIP_CODE], 17 Dec 1997) and GCP (ICH -
E6; 62 FR [ZIP_CODE], March 2018), as well as CFR Part 312 and applicable local regulations. 
2.3 Patient Information and Info rmed Consent  
A written informed consent in compliance with US Title 21 Code of Federal Regulations (CFR) 
Part [ADDRESS_1063922] address all questions raised by [CONTACT_102]. Each patient will read, assent to an understanding of, and sign the ICF or other locally applicable authorization form. Each patient will be made aware that he/she may withdraw from the study at any time. 
The Investigator will also sign the ICF and provide a cop y of the ICF to the patient. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063923] of Sponsor personnel responsible for study oversight is provided in the Study Reference 
Manual.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 18 4 INTRODUCTION 
Major depressive disorder (MDD) is a serious psychiatric disorder characterized by [CONTACT_774676][INVESTIGATOR_1841] (MDE) . Major depressive epi[INVESTIGATOR_143446]; however, the average age of onset is in the mid- 20s. The lifetime risk for MDD is estimated 
at 5% to 12% for men and 10% to 25% for women. Depression can have damaging effects on 
health and wellbeing, and leave one at risk for social withdrawal, alcohol abuse, and disrupted work, family, and social life ( Kupferberg et al, 2016). MDD has a high mortality rate and up to 
15% of patients with severe major depressive epi[INVESTIGATOR_143447]. In addition, individuals with MDD have high medical morbidity and are often plagued with more pain and physical illness than the general population. 
Despi[INVESTIGATOR_040] a number of approved antidepressants, a substantial percentage of individuals with MDD 
have inadequate response to conventional antidepressant s alone or in various combinations ( Little, 
2009). In STAR*D (Sequenced Treatment Alternatives to Relieve Depression), the largest randomized trial of the treatment of MDD, a representative sample of outpatients with MDD received one to four successive acute treatment steps. Those who did not achieve remission at each treatment step were able to move to the next step. Only  36.8% of patients achieved remission at 
step 1, the first course of antidepressant treatment ( Rush et al, 2005). More than 20% of those who 
failed to improve with the first treatment stopped taking medication, primarily within the first 2 weeks ( Warden, 2007).  Depressed p atients  who have an inadequate response to ADT represent 
a particularly vulnerable, at risk  population.  
Lumateperone (trade name [CONTACT_143508]
®) was approved by [CONTACT_390736] 
(FDA) on December 20, [ADDRESS_1063924] with mesolimbic/mesocortical 
selective modulation of phosphoprotein pathways downstream of dopamine receptors, serotonin reuptake inhibition, and indirect glutamatergic modulation ( Snyder et al, 2015). As a dopamine 
receptor protein phosphorylation modulator, lumateperone has dual properties, acting as post -
synaptic antagonist and as a pre -synaptic partial agonist at dopamine 2 (D
2) receptors in vivo , with 
mesolimbic/mesocortical selectivity. Lumateperone also increases the phosphorylation of the NR
2B, or GluN 2B, subunit of N -methyl-D- aspartate channels in extrastriatal dopamine- rich brain 
regions (eg, nucleus accumbens) and indirectly modulates glutamatergic (N MDA and AMPA) 
activity downstream from dopamine 1 (D 1) receptor activation.  
As a [ADDRESS_1063925] antidepressant efficacy with fewer side effects than selective serotonin reuptake inhibitors (Meltzer et al, 1989 ). Lumateperone’s indirect glutamatergic modulation in combi nation with 
serotonin reuptake inhibition may also play a role in  antidepressant response . Importantly, 
lumateperone lacks potent off -target interactions that have been associated with side effects of 
other antipsychotic drugs approved as adjunctive treatment of MDD. For example, lumateperone shows relatively weak affinity for 5- HT
2C and no measurable affinity for H [ADDRESS_1063926] the potential to treat depression ( Snyder 
et al, 2015). Antidepressant -like activity of lumateperone was measured using the social defeat 
(resident -intruder) mouse model. Mice exposed to repeated social defeat conditions display a 
reduced amount of time in contact [CONTACT_143471]- aggressive mice than normal controls. Such 
defeat behavior is reversed by [CONTACT_40328] (but not acute) treatment w ith clinically effective 
antidepressant drugs. In this model, lumateperone 1 mg/kg, administered once daily intraperitoneally for 28 days, reversed the defeat behavior, consistent with antidepressant efficacy.  
Brain -receptor target engagement was confirmed  in healthy male volunteers in Study ITI -007-003, 
the positron emission tomography (PET) Phase 1 clinical trial ( Davis et al, 2015). PET was used 
to determine dopamine D
2 receptor, serotonin transporter (SERT), and serotonin 5- HT 2A receptor 
occupancy in the brain at various times following single dose oral lumateperone administration. Lumateperone rapi[INVESTIGATOR_143448], showed long- lasting  and dose -related occupancy, and 
was generally safe and well -tolerated. Cortical 5 -HT
2A receptors were shown to be fully occupi[INVESTIGATOR_143449] 10 mg dose (>85% occupancy). A dose of lumateperone 40 mg achieved up to 39% striatal D
2 occupancy (average of 29%) and up to 31% striatal SERT occupancy (average of 22%). 
Together, these data confirm a central mechanism for lumateperone at dopaminergic and serotonergic brain targets.  
Clinical data from 3 well -controlled studies in patients with schizophrenia (Studies ITI -007-005, 
ITI-007- 301, and ITI -007- 302) are consistent with respect to the pharmacological profile and 
prediction for antidepressant effects with favorable safety and tolerability. In addition to improving psychotic symptoms, lumateperone also improved symptoms of depression in patients with schizophrenia and comorbid depression at basel ine. Similar improvements in depression 
symptoms were also seen i n a one- year open label study of lumateperone in patients with 
schizophrenia (ITI -007-303) . In this study, the favorable safety and tolerability profile was 
sustained .  
Clinical data from 3  well-controlled bipolar depression studies (Studies ITI -007- 401, ITI -007-404, 
and ITI -007-402) demonstrated efficacy in bipolar depression and confirmed lumateperone’s  
tolerability and  favorable safety profile.  
In Study ITI-007-404, once-daily lumateperone 42 mg met the primary endpoint with statistically significant improvement over placebo at Week 6 (study endpoint), as measured by [CONTACT_143472]- Åsberg Depression Rating Scale ( MADRS ) total score. Lumateperone 
42 mg also met the key secondary endpoint of statistically significant improvement on the Clinical Global Impression Scale, Bipolar version, Severity ( CGI-BP-S) total score and demonstrated 
statistically significant improvement o n the CGI- BP-S depression. 
In Study ITI -007- 402, once -daily lumateperone 42 mg adjunctive to lithium or valproate met the 
primary endpoint with statistically significant improvement over placebo at Week 6 (study endpoint), as measured by [CONTACT_143473]. Lumateperone 42 mg also met the key secondary endpoint of statistically significant improvement on the CGI -BP-S 
depression subscale.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 20 In Study ITI -007- 401, neither lumateperone dose (28 mg or 42 mg) met the primary endpoint of 
statistical separation from placebo as measured by [CONTACT_143473]. 
Patients who completed Study ITI -007- [ADDRESS_1063927] to their depressive symptoms . 
Safety data from these studies and other trials with lumateperone, which has been administered to 
more than 3300 individuals for up to one year, show lumateperone to be well tolerated across a  
dose range from 0.7 to 126 mg, with a safety profile similar to placebo.  
The purpose of the current study is to confirm the efficacy , safety  and tolerability  of lumateperone 
as adjunctive t herapy for the t reatment of patients with MDD. Patients will be monitored carefully 
for their mental health status and general health. Symptoms of depression may or may not improve 
during participation in this study; approximately half of the patients in this study will receive placebo. However, the information obtained from this study may help to treat people with depression in the future. More detailed information about the known and expected benefits and risks and reasonably expected AEs is provided in the  current  lumateperone Investigator’s 
Brochure. 
 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 21 5 STUDY OBJECTIVES  
5.1 Efficacy Objectives  
5.1.1 Primary Objective  
The primary efficacy objective of this study is to evaluate the efficacy of lumateperone 42  mg 
administered once daily compared with placebo as adjunctive treatment to antidepressant therapy 
(ADT) in patien ts with MDD who have an inadequate response to ongoing ADT as measured by 
[CONTACT_143467] 43 in the MADRS total score. 
The proposed estimand strategy to address the primary objective is as follows: 
• Target P opulation: Patients with MDD who have an inadequate response to ongoing 
ADT  
• Treatment : Lumateperone 42 mg vs placebo as adjunctive therapy to existing ADT 
• Variable ( Endpoint) : Change from baseline to Day 43 in the MADRS total score  
• Intercurrent events  (ICE)  and corresponding stra tegies  (see Table 5-1 ) 
• Summary measure: Difference in treatment means  between lumateperone 42 mg and 
placebo.  
 

Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 25 6 INVESTIGATIONAL PLAN 
6.1 Overall Study Design and Plan  
Study ITI-007-502 is a Phase 3, randomized, double -blind, plac ebo-controlled, multicenter study 
to evaluate the efficacy, safety , and tolerability of lumateperone as adjunctive therapy for the 
treatment of patients with M DD. This study will be performed at approximately 60 study centers 
in the [LOCATION_002] and globally.  
The study will be conducted as follows: 
• A Screening Period of up to 2 weeks  
• A 6-week Double-blind T reatment P eriod  
• A 1-week S afety Follow-up (SFU) P eriod  
The maximum study duration for each patient will be approximately 9 weeks.  
The study design schematic  is provided in Figure 6-1. The Schedule of E valuations is presented in  
Table 1-1. Detailed descriptions of the procedures conducted at each study visit are provided in 
Section 8.5. Figure 6-1: Schematic of Study Design  
 
ADT = antidepressant treatment; ET = early termination; SFU = Safety Follow -up. 
a Eligible patients who complete 6 weeks of double -blind treatment and provide informed consent to rollover into 
the Open -label Safety  Study will not enter the SFU Period.  

Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 26 6.2 Scientific Rationale for Study Design  
6.2.1 Study Design  
Screening Period (up to 2 Weeks)  
Potential patients will be evaluated during a Screening Period lasting up to 14 days. With approval 
from the Sponsor or designee, s hort extensions to the Screening Period may be granted in  
exceptional circumstances . After obtaining written informed consent, diagnostic interviews, 
determination of inadequate response to current ADT, and physical examinations will be 
conducted, vital signs and ECGs will be assessed, and blood samples will be collected for 
laboratory assessments. Patients considered potentially eligible will be required to continue their current ADT  but will be required to discontinue other psychotropic drugs.  
Evaluation of diagnostic validity and eligibility of each patient will be undertaken by [CONTACT_16015]. 
At Baseline (Visit 2), patients who continue to meet all eligibility criteria will be randomized to 
1 of 2 treatment arms , lumateperone 42 mg or matching placebo, and will enter the  6-week, double -
blind treatment period.  
Double-blind Treatment Period (6 Weeks)  
Patients will self -administer his/her first dose of study treatment  on the evening of the Baseline 
visit (Visit 2/ Day 1). A single dose will be taken each day in the evening, with or without food, 
for the duration of the 6- week Double -blind Treatment Period. Antidepressant treatment will also 
continue as previously prescribed. The dose and frequency of ADT  must not change during the 
Screening Period or for the duration of the Double-blind T reatment Period. 
Patients will attend outpatient study visits on Days 8, 15, 22, 29, 36, and 43. With approval from 
the Sponsor or designee,  sites will be permitted to conduct remote visits if a site -based visit is not 
feasible. However, all Screening (Visit 1) and Baseline (Visit 2) assessments must be performed 
in person.  
A patient will be defined as a treatment completer if the patient complete s the Double-blind 
Treatment Period (all scheduled visits up to and including Visit 8). Patients who withdraw 
prematurely  should be seen for an Early Termination (ET) visit as soon as possible and will also 
be asked to return for a safety follow-up visit approximately one week after Vi sit 8/ET. 
Safety Follow-up Period (1 Week)  
All patients should return to the clinic for the SFU  visit approximately 1 week after Visit 8/ET . 
Any ongoing AEs at the S FU visit must be followed until resolution, until the AE stabilizes, until 
it is determine d to be not clinically significant, or until the patient is lost to follow -up. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 27 6.2.2 Separate Open -label Safety Study  
Patients who complete the 6 -week Double-blind T reatment Period , who are considered to be 
appropriate by [CONTACT_737], and who meet eligibility criteria  may enroll in the 6 -month Open-
label Safety Study at the Visit 8/Week 6 visit. This rollover visit to the Open-l abel Safety Study at 
Visit 8/Week [ADDRESS_1063928] 
a SFU  visit (Visit 9/Week  7). 
6.2.3 Dose Selection  
Lumateperone 42 mg was selected based on the efficacy seen with this dose in bipolar depression 
studies ITI -007- 404 and ITI -007- 402. This dose delivers full occupancy of the cortical 5- HT 2A 
receptors (>85% occupancy) with modest striatal D 2 receptor occupancy and SERT occupancy. 
Data from human PET brain receptor occupancy studies with lumateperone indicate that a dose as low as 10 mg is associated with >85% occupancy of cortical 5- HT
2A receptors, while the 42- mg 
dose demonstrates approximately 40% striatal D 2 receptor occupancy. SERT occupancy has been 
demonstrated to be comparable to D 2 receptor occupancy. Moreover, in patients with 
schizophrenia and bipolar depression, once -daily oral administration of lumateperone 42 mg has 
been well tolerated with no dose titration needed and with a safety profile similar to placebo with up to 6 weeks treatment duration. Therefore, a fixed- dose design will be employed in this study 
with once daily oral administration of lumateperone 42 mg (or placebo).  
A placebo control group is needed to establish the efficacy of a new indication . The 6- week 
treatment period duration was chosen because it is considered an acceptable period to demonstrate 
efficacy in this  patient population. The hypothesis of this study is that lumateperone [ADDRESS_1063929] for the treatment of MDD, with statistically significant 
superiority vs placebo on the primary outcome measure: C hange from baseline to Day  [ADDRESS_1063930] meet the following inclusion criteria:  
1. Provide written informed consent obtained from the patient before the initiation of any study specific procedures. See Appendix I  for informed consent requirements; 
2. Male or female patients between the ages 18 and  65 years; in clusive; 
3. Meet DSM -5 diagnostic criteria for  MDD (a diagnosis of MDD with psychotic features will 
be acceptable)  as confirmed by [CONTACT_9304] -approved rater using the Mini -
International Neuropsychiatric Interview (MINI) , and meet all  the following criteria:  
a. The start of the current MDE is at least 8 weeks but no more than 18 months prior 
to the Screening (Visit 1);  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063931] moderate severity of illness, based on rater  administered MADRS total 
score ≥  24 at Screening (Visit 1) and at Baseline (Visit 2);  
c. Has at least moderate severity of illness  based on CGI-S score of ≥ 4 at Screening 
(Visit 1) and at Baseline (Visit 2);  
d. Has a QIDS -SR-16 score of >14 at Screening (Visit 1) and at Baseline (Visit 2); 
e. Has sufficient history and medical re cord confirmation (as defined in the Stu dy 
Reference Manual)  verifying ADT and the current MDE is causing clinically 
significant distress or impairment in social, occupational, or other important areas 
of functioning; 
4. Currently having an inadequate response to ADT (less than 50% improvement) as confirmed 
by [CONTACT_143474] (per package 
insert) of one of the following antidepressant s as monotherapy treatment for at leas t 6 weeks 
duration, and: 
a. citalopram/escitalopram 
b. fluoxetine  
c. paroxetine 
d. sertraline  
e. duloxetine 
f. levomilnacipra n/milna cipran  (if locally approved for MDD ) 
g. venlafaxine/desvenlafaxine 
h. bupropi[INVESTIGATOR_2394] 
i. vilazodone 
j. vortioxetine 
5. Is currently an outpatient, and is anticipated to maintain outpatient status for the duration of 
the study; 
6. Has a body mass index (BMI) of 19–40 kg/m2, inclusive; 
7. Ability to follow study instructions and likely to complete all required visits.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 29 6.3.2 Exclusion Criteria  
Patients who meet any of the  following exclusion criteria will not be eligible to participate in the 
study. 
Psychiatric Criteria:  
1. Within the patient’s lifetime, has a confirmed DSM -5 psychiatric diagnosis other than MDD, 
including: 
a. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other 
psychotic disorde r;  
b. Bipolar Disorder.  
2. Within 6 months of Screening, has a confirmed DSM -5 psychiatric diagnosis other than  MDD, 
including:  
a. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessi ve-
compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note : 
anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require con current treatment; 
b. Eating disorder;  
c. Substance use disorders (excluding nicotine)  
d. Personality disorder of sufficient severity to have a major impact on the patient’s psychiatric status; 
e. Within 12 m onths of Screen ing, has had any other psychiatric condition (other than 
MDD) that has been the main focus of tre atment . 
3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening (Visit 1) and Baseline (Visit 2);  
4. The patient experiences a ≥ 25% decrease in the QIDS -SR-16 total score between Screening 
(Visit 1) and Baseline (Visit 2);  
5. In the opi[INVESTIGATOR_689], the patient has a significant risk for suicidal behavior during his/her participation in the study or  
a. At Screening (Visit 1), the patient scores “yes” on Suicidal Ideation Items 4 or 5 of 
the C -SSRS with in 6 month s prior to S creening  or, at Baseline (Visit 2) , the patient 
scores “yes” on Suicidal Ideation Items 4 or 5 since the Screening Visit; 
b. At Screening (Visit 1), the patient has had 1 or more suicidal attempts with in the  2 
years  prior to S creening; or  
c. At Screening (Visit 1) or Baseline (Visit 2),  the patient  scores ≥ 5 on MADRS Item 10 
(Suicidal Thoughts); or  
d. The patient is c onsidered to be an imminent danger to him/herself or others . 
6. The patient has a first MDE  at age 60  years  or older.  
 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 30 Treatment Criteria:  
7. In the current MDE , the patient has had > 2 ADTs administered at adequate dose (per  product 
label) and for an adequate duration (at least 6 weeks) ; 
8. In the current MDE, the patient has not responded to treatment  with an antipsychotic  for MDD  
administered at an adequate dose (per product label)  and for an adequate duration (at least 
3 weeks) ; 
9. The patient is considered treatment -resistant, defined as having a lifetime history of treatment 
resistance (no remission) to > 3 treatments with medications approved for the treatment of 
MDD at an adequate dose (per product label) and for an adequate dura tion of at least 6 weeks  
for monotherapy and 3 weeks for adjunctive therapy);  
10. The patient has received electroconvulsive therapy (ECT) , vagal nerve stimulation, or 
repetitive trans -cranial magnetic stimulation  within the past [ADDRESS_1063932] at any time; 
11. The patient has known hypersensitivity or intolerance to lumateperone,  or to any of the 
excipi[INVESTIGATOR_840];   
12. The patient is currently participating in psychotherapy, or has plans to initiate psychotherapy 
therapy during the study;  
13. The p atient has used 1 of the following agents under the specified conditions: 
a. Any strong cytochrome P450 3A4 inhibitor or any P450 3A4 inducer within 7 days prior to the baseline visit; 
b. Monoamine oxidase inhibitors within 14 days prior to the baseline visit; 
c. Other d rugs with known psychotropic properties or any non- psychotropic drugs 
with known or potentially significant central nervous system effects as reviewed by [CONTACT_16015], taken after  screening, including, but not limited to: 
i. Benzodiazepi[INVESTIGATOR_143450] ( except ions for zolpi[INVESTIGATOR_143451] s for insomnia are described in Section 7.7.3- Rescue 
Medications );  
ii. Central opi[INVESTIGATOR_74453]/antagonists including tramadol; 
iii. Anticonvulsants, mood stabilizers, antidepressants other than background 
antidepressant treatment,  stimulants, antipsychotics, and non-
benzodiazepi[INVESTIGATOR_143452]; 
iv. Dietary supplements and medical foods unless approved by [CONTACT_16015] . Daily multivitamin use is not excluded; 
14. The patient has participated in a previous clinical trial with lumateperone, or  has had exposure 
to any investigational product within [ADDRESS_1063933] 
3 years in > [ADDRESS_1063934] with a central nervous system 
indication; 
15. The patient is unable to be safely  discontinued from prohibited psychotropic or non-
psychotropic medication (in the  opi[INVESTIGATOR_689]). 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 31 Other Medical Criteria:  
16.  The patient is male, or female of childbear ing potential, and does not agree to use a highly 
effective method of birth control (defined as those methods, alone or in combination, that result 
in a failure rate less than 1 percent per year when used consistently and correctly) beginning 
with signing the Informed Consent Form through the end-of- study follow -up period. (F emales  
of non- childbearing potential (defined as either permanently sterilized ) or post -menopausal 
females ( defined as at least one year with no menses without an alternative me dical 
explanation) are exempt from the birth control requirement; 
17. The patient is breast -feeding  or pregnant. Female patients of childbearing potential must have 
a negative serum pregnancy test at Screening (Visit 1). On Day 1 (Baseline/Visit 2), female patients of childbearing potential must have a negative urine pregnancy test prior to study 
treatment  administration; 
18. The patient has a positive test for drugs of abuse (eg, amphetamines, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine metabolites, methadone, opi[INVESTIGATOR_858], or phencyclidine) at Screening (Visit 1) . Exceptions may include prescription treatments (eg, opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651]) if the use is not chronic and is able to be discontinued as per the Investigator with the concurrence of the Sponsor or d esignee. A repeat drug test is allowed with the 
approval of the Sponsor  or designee. A negative urine drug screen ( UDS ) is required for 
randomization. 
19. The patient has abnormal laboratory values or clinical findings at Screening ( Visit 1) that are 
judged to be clinically significant including, but not limited to: 
a. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2 × the upper limit of normal (ULN);  
b. Total bilirubin > 1.5 × ULN; 
c. Hemoglobin < 8 g/dL (80 g/L) for females and < 9 g/dL (90 g/L) for males; 
d. Absolute neutrophil count (ANC) < 1200 cells/µL (1.2 × 10
9/L); 
e. Thyroid- stimulating hormone (TSH) outside of normal reference range AND free 
T3 or free T4 outside of the reference range. Free T3 and Free T4 will only be evaluated if TSH is outside of reference range;  
f. HbA1c >7.5% [>58 mmol/mol];  
g. Positive test for hepatitis B surface antigen and/or hepatitis B core antibody immunoglobulin M at screening; positive hepatitis C antibody at screening (Visit 1), with the exception of a patient for whom the reflex HCV RNA test is 
negative;  
h. Any other clinically significant abnormal laboratory result obtained at Screening (Visit 1); 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 32 20. The patient ha s corrected QT interval using the Fridericia formula (QTcF)  >450 msec for males 
or > 470 msec for females, corrected QT interval using the Bazett formula (QT cB) >450 msec 
for males or >470 msec for females, and/or heart rate < 50 bpm, or evidence of clinically 
significant bundle- branch blocks; 
21. The patient has any of the following conditions:  
a. Cardiac: uncontrolled angina, or history of a myocardial infarction within 3 months 
prior to screening, or history of a clinically significant cardiac arrhythmia including antipsychotic drug-induced corrected QT interval prolongation);  
b. Malignancy : Any diagnosis of cancer (except basal or squamous cell skin 
carcinoma), unless in remission for at least 5 years; 
c. Gastrointestinal: history of gastric by[CONTACT_143475]; 
d. Endocrine : hypo- or hyperthyroidism unless treat ed and stable with no medication 
changes for at least three months prior to screening, diabetes, unless considered stable with no changes in treatment for at least three months prior to screening; 
e. Hepatic: Hep atitis  B or Hep atitis  C; moderate or severe hep atic impairment (Child 
Pugh B or C)  
f. Pulmonary: history of diagnosed and untreated obstructive sleep apnea;  
g. Neurological: history of epi[INVESTIGATOR_002], seizure or convulsion, or electroencephalogram 
with clinically significant abnormalities, delirium, dementia, amnestic, or central 
sleep apnea, or significant brain trauma , or other cognitive disorder; 
h. Infectious : History of human immunodeficiency virus (HIV) infection. 
Note: Any other medical condition, or medical conditions  that are stable with treatment (eg, 
hypertension, hypercholesterolemia, or thyroid abnormalities) are allowed as long as the condition 
has been stable for at lea st 3 months prior to Screening  (Visit 1) ; treatments  for these conditions 
are documented , kept stable , and are expected to be unchanged during the study; and the condition 
is not thought to affect safe participation in the study or relevant study outcomes in the opi[INVESTIGATOR_774670]. 
Other Criteria:  
22. The patient is judged by [CONTACT_143476];  
23. The patient is an employee of the Investigator or study site, or immediate family (ie, spouse, parent, child, or sibling, whether biological or legally adopted) of such employees, the Investigator, the Sponsor, or contract research organizations (CROs) conducting the study. 
6.4 Stoppi[INVESTIGATOR_143454] -level discontinuation or stoppi[INVESTIGATOR_143455] -
stoppi[INVESTIGATOR_3418]. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 33 6.4.1 Discontinuation of Patients from Therapy or Assessment: Patient -level Stoppi[INVESTIGATOR_134248]  
A premature discontinuation will occur when a patient who signed the ICF ceases participation in 
the study, regardless of circumstances, before the completion of all study visits and procedures. Patients can be prematurely discontinued from the tr eatment period  for one of the following 
reasons:  
• Death  
• AE 
• Lack of efficacy ( patients whose MDD symptoms worsen or are determined by [CONTACT_143477] -blind 
treatment period may be withdrawn from the study to start appropriate treatment at the 
Investigator’s discretion ) 
• Protocol violation 
• Study terminated by [CONTACT_2728] 
• Site terminated by [CONTACT_2728] 
• Withdrawal by [CONTACT_143478] 
• Lost to follow -up (every effort must be made to contact [CONTACT_102]; a certified/traceable 
letter must be sent)  
• Pregnancy  
• Other ( such as physician decision, administrative reasons , etc) 
NOTE : If a patient discontinues due to withdrawal of consent and either a concurrent AE was 
reported  or concurrent lack of efficacy was documented , the study site should query and confirm  
the primary reason for discontinuation and record the primary reason for discontinuation on the 
electronic case report form (eCRF).  
Patients who discontinue from the study and do not return to the study center for final assessments must be requested in writing to return to the study center for a final assessment. A copy of the letter, together with the source documentation, will be kept in the Investigator’s files. The reason for prema ture discontinuation from the study will be recorded on the Study Termination Page of 
the eCRF. Study center staff may be contact[CONTACT_143479]. 
All patients who prematurely discontinue from the study regardless of cause should be  seen for a 
final assessment  at an ET Visit. All patients who prematurely discontinue from the study should 
return for the safety follow-up visit. 6.4.[ADDRESS_1063935] , all safety data ( adverse events, clinical laboratory 
measures , vital signs, ECGs , and C- SSRS)  will be reviewed in a blinded manner . If the Study 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063936] of the Study  
Any amendment to this protocol will be provided by [CONTACT_143480]. No 
protocol amendment may be implemented before it has been approved by [CONTACT_1201]/IEC and Competent Authorities ( if applicable), and the signature [CONTACT_3264], signed by [CONTACT_737], has been 
received by [CONTACT_1034]. If the protocol is amended to eliminate or reduce the risk to patients, the amendment may be implemented before IRB/IEC and Competent Authority review and approval. However, the IRB/IEC and the Competent Authority must be informed in writing of such an 
amendment, and approval must be obtained within reasonable time limits. Administrative changes, 
such as changes in study personnel, will be s pecified  in the Study Reference Manual. 
Adminis trativ e changes will not require a protocol amendment.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063937] will contain a sufficient quantity of capsules for 1 patient for 
1 week (7 doses, plus 3 extra dose s), to be dispensed at every visit during the 6- week treatment 
period. The study treatment  blister card will contain one 1× [ADDRESS_1063938] will be labeled according to local laws and regulations. Table 7-2: Weekly Study Treatment  Cards  
Treatment  Card Contents  
Lumateperone 42 mg  One 1 ×10 strip of lumateperone 42 -mg capsule  
Placebo  One 1 ×10 strip of lumateperone -matched placebo  
Note: Each card will hold [ADDRESS_1063939] be accounted for. In addition, at the end of the 
study, all unused study treatment  and empty study treatment packages should be returned to the 
Sponsor or designee or destroyed, as per instructions provided by [CONTACT_1034]. 7.3 Method of Assigning Patients to Treatment Groups  
After a patient signs the ICF at Screening (Visit 1), site personnel will re gister the patient in the 
interactive web response system (IWRS) . 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 37 Study treatment  will be labeled with medication kit numbers. The IWRS will provide the study 
center with the specific medication kit number(s) for each patient at the time of randomization. 
Unblinded biostatistics personnel not participating in the conduct of the study w ill generate a 
permuted block randomization schedule using SAS software Version 9.4 or newer for I WRS, 
which will link sequential patient randomization numbers to treatment codes. In the event that the blind needs to be broken because of a medical emergency, the Investigator may unblind an individual patient’s treatment allocation ( Section 7.5). 
Study center personnel will dispense study treatment  accor ding to the IWRS instructions. Study 
center personnel will also log onto the IWRS at subsequent visits to obtain a study treatment  kit 
number for dispensing study treatment. Study centers will receive the IWRS confirmation notifications for each transactio n. All notifications are to be maintained with the study source 
documents. 
7.[ADDRESS_1063940] be provided if the blind 
is broken. Before study treatment  is unblinded, every attempt should be made to discuss the case 
with the Sponsor or designee . Breaking the code at the study center will immediately disqualify 
the patient from further participation in the study.  
Treatment codes may be broken by [CONTACT_143481]. In such cases, 
the study center staff will be kept blinded and the patient will not need to be disqualified from the study. 
For IWRS Unblinding  
In an emergency, the Investigator can obtain the treatment assignment of any patient at his/her 
study center through the I WRS. In an emergency, the Investigator will ac cess the IWRS to break 
the blind. 
7.[ADDRESS_1063941] be carefully 
documented. These errors may include providing the wrong dose, not taking the dose as prescribed, or losing medication. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 38 In addition, at every visit, study staff will ask the patient about compliance with prescribed ADT 
dosing regimen.  
Any exceptions to non- compliance due to unusual circumstances should be discussed with the 
Sponsor or designee. 7.7 Prior and Concomitant Medications 
Use of all concomitant medications will be recorded in the patient’s eCRF. Drug name [CONTACT_143509], herbal products, vitamins, minerals, and over-the-counter medications. Any changes in concomitant medications will also be recorded in the patient’s eCRF. Any concomitant medication deemed necessa ry for the welfare of the patient 
during the study may be given at the discretion of the Investigator, e g, limited , acute prescribed 
opi[INVESTIGATOR_2441] . However, it is the responsibility of the Investigator to ensure that complete details 
regarding the medication are recorded in the eCRF.  
7.7.[ADDRESS_1063942] during the Screening Phase lasting up to 2 weeks . A washout is not 
required for non- psychotropic medications; however, certain medications do have stability 
requirements as presented in the eligibility criteria. Medication history, including the use of psychotropic medication or of any other medication, should be recorded at Screen ing ( Visit 1 ). 
Thereafter, any changes in concomitant medications or new medications should be recorded in the eCRF .  
7.7.2 Prohibited Medications  
Use of the following products during the study is prohibited: alcohol, cannabis, illicit drugs,  any 
known 5- HT
2A receptor antagonist or inverse agonist, any strong cytochrome P450 3A4 inhibitor 
or inducer, or any drugs with known psychotropic properties or any non- psychotropic drugs with 
potential central nervous system effects. 
Patients who have been taking a low dose  of quetiapi[INVESTIGATOR_050] (< 50 mg) for the treatment of insomnia 
must discontinue quetiapi[INVESTIGATOR_143456] (Visit 1).  
7.7.[ADDRESS_1063943] 2 weeks of the double -blind 
treatment period only ( Section 6.3.2, Exclusion 13)  for the treatment of in somnia. If zolpi[INVESTIGATOR_143457], another sedative hypnotic may be approved by [CONTACT_95346]. 
The date of each dose of rescue medication administration as well as the name [CONTACT_774679].  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 39 7.8 Treatment After Discontinuation  
Patients whose depressive symptoms worsen or are determined by [CONTACT_143482]-blind T reatment Period may, at the 
Investigator’s discretion, be discontinued from the Double- blind T reatment Period in order to start 
appropriate treatment. This new treatment will not be provided by [CONTACT_1034]. Patients who 
initiate a new treatment during the study must be discontinued from the study and should also 
return for a  Safety Follow -up visit. 
All patients who prematurely discontinue from the Double- blind Treatment Period regardless of 
cause should be  seen for a final assessment at the ET Visit. All patients who prematurely 
discontinue from the Double- blind Treatment Period  should return for the Safety Follow-up visit.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063944] meet the DSM -5 criteria for diagnosis of Major 
Depressive Disorder, as confirmed by [CONTACT_42145] (7.0.2; 8/8/16 version). The MINI is a validated 
clinical diagnostic tool ( Sheehan et al, 1998) that will be used at the S creening  visit only and will 
be completed by a Sponsor- approved rater.  
8.1.2 MGH Antidepressant Treatment Response Questionnaire  (ATRQ)  
The [LOCATION_005] General Hospi[INVESTIGATOR_135418] ( ATRQ) 
(Chandler et al, 2010 ) is a clinician -administer ed scale used to determine treatment resistance in 
Major Depressive Disorder. The scale def ines [ADDRESS_1063945] commo nly used antidepressant s. 
8.1.3 Medical History and Other Information  
Medical history information will be collected at screening and should include demographic 
information  (as allowed by [CONTACT_143483]), current and past medical conditions, and 
current and past medications. Prior to study treatment  administration, medical history must be 
documented in the patient’s study chart and also recorded in the appropriate eCRF.  
Patients will be checked for previous participation in an ITI -007 clinical study and for duplicate 
enrollment by [CONTACT_108575] t hrough Verified Clinical Trials (VCT).  
8.1.4 Eligibility Review Process  
Eligibility of potential patients will be confirmed  by [CONTACT_143485] a review of 
screening data, including safety and laboratory assessments, medical and psychiatric histor y, 
including the ATRQ , and psychiatric status , including DSM -5 diagnosis of MDD, as confirmed 
by [CONTACT_42145] , and MADRS , CGI-S, and QIDS -SR-16 scores . Further information regarding the 
eligibility review process and the Pre -Enrollment Eligibility Review (PEER)  Form  are provided 
in the Study Reference Manual. 8.1.5 Patient Placebo  Questionnaire and Training  
A brief training module will be provided describing placebo response at Baseline (Visit 2)  prior to 
randomization. A placebo response questionnaire will be administered at Baseline (Visit 2) prior 
to randomization to assess the patient’s perception of likelihood their symptoms will improve as 
well as their perception at the end of the study whether they received placebo or active study treatment . 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 41 8.1.6 Quick Inventory for Depressive Symptomatology- Self Report (QIDS -SR-16) 
The QIDS -SR-16 is a 16 -item patient-r ated scale of symptom severity in depression. It assesses 
nine key symptoms of depression: insomnia/hypersomnia, low mood, appetite/weight changes, 
impaired self -perception, concentration difficulties, loss of interest/pleasure, suicidal ideation, 
psychomotor agitation and fatigue . Respondents use a 4- point Likert -type scale (0-3) to assess 
their behaviors and mood over the course of the past week.  The total score ranges from 0 -27, with 
higher scores indicating more severe depression.  
8.2 Efficacy Assessments  
8.2.1 Montgomery -Åsberg Depression Rating Scale (MADRS)  
The MADRS is a 10 -item scale designed to measure the overall severity of depressive symptoms 
(Montgomery and Åsberg, 1979). Individual items are rated by [CONTACT_9304] -
approved rater on a scale of [ADDRESS_1063946]. The MADRS total score ranges from 0 to 60. The MADRS total score at screening is a major 
inclusion criterion of the study, as well as the primary outcome measure for the study. The MADRS 
will be completed by a Sponsor- approved rater.  
8.2.2 Clinical Global Impression -Severity  (CGI -S) 
The Clinical Global Impression Scale -Severity provides the clinician’s assessment of the overall 
severity of the patient’s psychopathology ( Guy, 1976). The CGI -S asks the clinician: “Considering 
your total clinical experience with this particular population, how mentally ill is the patient at this time?” which is rated on the following seven- point scale: 1=normal, not at all ill; 2=borderline 
mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among  the most 
extremely ill patients. The CGI -S will be completed by a Sponsor- approved rater.  
8.2.3 Changes in Sexual Functioning Questionnaire  
The Changes in Sexual Functioning Questionnaire (CSFQ) is a structured interview/questionnaire designed to measure illness - and medication -related changes in sexual functioning (Keller et al, 
2006). The CSFQ -[ADDRESS_1063947] higher sexual functioning. For 12 of the 14 items, higher sexual functioning corresponds to greater frequency or enjoyment/pleasure (eg, 1 = never to 5 = every day). For two items (Item 10, assessing loss of interest after arousal fo r women and priapi[INVESTIGATOR_82508], and I tem 14, assessing 
painful orgasm), higher sexual functioning corresponds to lower frequency (e g, 1 = every day to 
5 = never). Items 10 and 14 are included in the total score but not in any scale score. Gender -
specific versions of the CSFQ-14 will be administered during the study. 
 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 42 8.3 Safety   
All patients who receive study treatment  will be evaluated for safety. Safety assessments will 
include incidence of AEs, C -SSRS assessment for suicidality, EPS assessment as measured by 
[CONTACT_143486], BARS, and SAS scales, clinical laboratory evaluations, ECG evaluations, vital sign 
measurements, and physical examination. Additional details pertaining to safety assessments are provided in the Schedule of Evaluations ( Table 1-1).  
8.3.1 Adverse Events  
[IP_ADDRESS] Definition of Adverse Event  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (ICH-E2A; 21 CFR 312.32[a]). 
NOTE:  Medical procedures scheduled prior to obtaining informed consent but occurring during 
the study and for a pre -existing condition which did not worsen should not be captured as AEs but 
the medical reason for the procedure should be listed in the medical history if related to a pre -
existing condition. [IP_ADDRESS] Definition of Serious Ad verse Event  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life threatening  
NOTE: An AE is considered "life -threatening" if, in the view of either the Investigator or Sponsor, 
its occurrence places the patient at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death. 
• Requires inpatient hospi[INVESTIGATOR_1081] 
• Results in persistent or significant disability/incapacity, or  
• Is a congenital anomaly/birth defect 
Important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_708], based on appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in patient hospi[INVESTIGATOR_059], or the development of study treatment dependency or drug abuse. 
Emergency room visits that do not result in hospi[INVESTIGATOR_774671] a s SAEs . 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 43 [IP_ADDRESS] Classification of Adverse Events and Serious Adverse Events  
[IP_ADDRESS].1 Severity  
The Investigator will provide an assessment of the severity of each AE by [CONTACT_44745] a severity 
rating on the appropriate AE reporting page of the patient’s eCRF. Severity,  which is a description 
of the intensity of manifestation of the AE, is distinct from seriousness,  which implies a patient 
outcome or AE -required treatment measure associated with a threat to life or functionality 
(Section  [IP_ADDRESS]).  
Severity will be assessed according to the following scale:  
Mild:  A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities 
of daily living. 
Moderate:  A type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, cau sing 
discomfort but poses no significant or permanent risk of harm to the research patient.  
Severe:  A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.  
[IP_ADDRESS].[ADDRESS_1063948] be assessed by [CONTACT_16134]:
 
Is there a reasonable possibility the study treatment  caused the event?  
Yes: There is evidence to suggest a causal relationship between the study treatment  and 
adverse event, ie:  
• There is a reasonable temporal relationship between the study treatment  and the event, 
and/or  
• The event is unlikely to be attributed to underlying/concurrent disease, other investigational products, or other factors, and/or 
• Positive dechallenge and/or rechallenge exist  
OR 
No: There is no evidence to suggest a causal relationship between the study treatment  and 
adverse event, ie:  
• There is no reasonable temporal relationship between the study treatment  and the event, or  
• The patient did not take the study treatment, or 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 44 • The event is likely to be attributed to underlying/concurrent disease, other investigational 
products, or othe r factors.  
There may be situations in which an SAE has occurred, and the Investigator has minimal information to include in the initial report to the Sponsor. However, it is important that the Investigator always makes an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor. The Investigator may change his/her opi[INVESTIGATOR_9242] -up information and send an SAE follow -up report with the updated 
causality assessment.  
For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality. The causality assessment must be recorded on the appropriate AE reporting page of the patient’s eCRF. 
[IP_ADDRESS] Time Period and Frequency  of AE and SAE Reporting  
The Investigator will report all AEs from the time informed consent was obtained until the final  
protocol-defined study visit or last known dose date of study drug + [ADDRESS_1063949] occurred since the previous  
visit. Patients will be asked to volunteer information with a nonleading question such as, “How do 
you feel since your last visit?”   
[IP_ADDRESS] Adverse Event Reporting Procedures  
[IP_ADDRESS].[ADDRESS_1063950] be recorded on the appropriate AE reporting page of the patient’s eCRF whether 
or not they are considered causally related to study treatment.  
For every AE, the Investigator must: 
• Provide an assessment of the seriousness of the event (ie, is it an SA E?), as well as the 
severity and casual relationship. See Section [IP_ADDRESS] for the definition of SAEs and 
Section [IP_ADDRESS].2 for SAE reporting procedures. 
• Document all actions taken with regard to study treatment; 
• Detail any other treatment measures taken for the AE.  
Any AEs that are ongoing at the time of the final protocol- defined study visit will be followed 
until the condition returns to pre -study status, has resolved or stabilized, or can be explained as 
being unrelated to study treatment . If a follow -up visit is deemed necessary for appropr iate safety 
surveillance, it will take place within 30 days of the final protocol-defined study visit. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 45 [IP_ADDRESS].[ADDRESS_1063951] report the event to ProPharma Group on the SA E Form. 
In addition to completing the SAE form, the Study Physician may also be notified by [CONTACT_756]. 
If, during follow -up, any nonserious AE worsens and eventually meets any SAE criterion, that AE 
should be recorded as a new SAE.  
Preplanned hospi[INVESTIGATOR_602] (eg, elective procedures for pre -existing conditions that did not 
worsen, such as cosmetic surgery and hysterectomy) are excluded from SAE reporting. The study center must email or fax the SAE form to the SAE email address below. Even if an 
initial report is made by [CONTACT_756], the SAE form containing all available details must still be emailed or faxed within [ADDRESS_1063952] be recorded on the appropriate pages of the patient’s eCRF. All SAEs will be followed until resolution or stabilization. The Sponsor may contact [CONTACT_143487]. A response is required within [ADDRESS_1063953].  
SAE Reporting E- mail: [EMAIL_2427]   
SAE Reporting Fax Number: +1  ([PHONE_3191] 
Medical Emergency Phone Number: US: +[PHONE_3192]; outside of US : +44  [PHONE_3193]. 
8.3.2 Potential Hy’s Law Cases 
Study center personnel must report every patient who meets potential Hy’s Law criteria from the time the ICF is signed until [ADDRESS_1063954] known 
dose of study treatment (if the final visit does not occur). The criteria for potential Hy’s law cases are as follows:  
• ALT or AST ≥ 3 × ULN and  
• Total bilirubin ≥ 2 × ULN and  
• Alkaline phosphatase < 2 × ULN  
Study center personnel must report every subject who meets these potential criteria. Typi[INVESTIGATOR_897], these analytes will be obtained from the same sample, but they may come from multiple samples 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063955] known dose of study treatment. 
A laboratory alert for potential Hy’s  Laws cases will be in place, and the laboratory must notify 
Investigators and the Sponsor immediately when the above criteria have been met. The Sponsor 
must be notified of any potential Hy’s Law case as soon as possible (within 24 hours of learning of a potential Hy’s Law case). Refer to the SAE reporting procedures ( Section [IP_ADDRESS].2) even if 
no AE has occurred. 
Every effort to determine the cause of the liver enzyme abnormalities must be made, and close 
monitoring should be initiated in conjunction with the Study Physician and in accordance with the FDA Guidance for Industry: Drug Induced Liver Injury—Pre -Marketing Clinical Evaluation, 
July 2009. 
8.3.[ADDRESS_1063956] known dose of study treatment (if a final visit does not occur) . 
Within [ADDRESS_1063957] report the event to the Sponsor on the Pregnancy Notification Form and email  or fax it to the email address or fax number 
below even if no AE has occurred.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. If the pregnancy is associated with an SAE (eg, spontaneous 
miscarriage or if the  mother is hospi[INVESTIGATOR_143460]), a separate SAE form must 
be filed as described in Section [IP_ADDRESS].2 with the appropriate serious criterion (eg, 
hospi[INVESTIGATOR_059]) indicated in addition to the Pregnancy Notification/Outcome Form. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported as such. 
Any pregnancy in a study patient or in a female partner of a male study patient/subject must be 
followed to term/termination. The outcome, including status of the mother and the child, must be reported to the Sponsor by [CONTACT_12550] a follow-up Pregnancy Outcome Form.  
Pregnancy Reporting E- mail: [EMAIL_2427]  
Pregnancy Reporting Fax Number: +[PHONE_3194]. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 47 8.3.4 Clinical Laboratory Determinations 
Blood and urine samples for clinical laboratory tests will be collected as specified in the Schedul e 
of Evaluations  (Table 1-1). Patients are required to fast for at least 10 hours before the collection 
of clinical laboratory blood tests at designated  visits .  
During Screening, the Investigator/sub- Investigator should assess the clinical significance of any 
values that are outside the reference ranges provided by [CONTACT_2237]. Patients with 
abnormal screening laboratory results judged to be clinically significant will be excluded from the study. 
Laboratory results should be reviewed by [CONTACT_737]/sub- investigator throughout the study. 
For safety reasons or at the discretion of the Investigator, repeat laboratory assessments may be 
perfo rmed at an unscheduled visit. 
The following clinical laboratory levels will be measured: 
• Hematology: hematocrit; hemoglobin; red blood cell count with indices (mean 
corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentrat ion); reticulocytes; white blood cell count and differential (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils) reported as percent (%) and absolute values; and platelet count.  
• Chemistry : albumin; alkaline phosphatase; ALT;  AST; bilirubin (total, direct); blood 
urea nitrogen; calcium; chloride; cholesterol (high -density lipoprotein [HDL] and low -
density lipoprotein [LDL] will be calculated and reported); creatinine; creatine phosphokinase; gamma -glutamyl transferase; glucose; insulin; lactate dehydrogenase; 
phosphate; potassium; prolactin; sodium; triglycerides; total protein; uric acid.  HbA1c 
and TSH (reflex free T3 and free T4) will be measured at Screening/Visit 1 and Visit 8/ET only.  
• Urinalysis : macroscopic (pH, specific gravity, glucose, protein, ketones, bilirubin, 
nitrates, blood) and microscopic (red blood cells/high- power field, white blood 
cells/high -power field, casts, epi[INVESTIGATOR_1663], crystals, granulation). 
• Urine Drug Screen (UDS) : Urine drug  tests for amphetamines, barbiturates , 
benzodiazepi[INVESTIGATOR_1651], cannabinoids , cocaine metabolites, methadone, opi[INVESTIGATOR_858], or 
phencyclidine will be performed. Any patient who tests positive for any drug at 
Screening , will be excluded from participating in the study. Exceptions may include  
prescription treatments (eg, opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651]) if the use is not chronic and is able to be discontinued as per the Investigator with the concurrence of the Sponsor  or 
designee. A  repeat drug test is allowed with the approval of the Sponsor  or designee. 
A negative UDS is required for randomization. 
Additional information regarding sample collection, processing, and shippi[INVESTIGATOR_774672]. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 48 • Urine and s erum pregnancy t ests: Female patients who are of childbearing potential 
will undergo a serum  pregnancy test at Screening (Visit 1) and a urine pregnancy test 
at Baseline ( Visit 2) at the study clinic, and, at the discretion of the Investigator, at an 
Unscheduled Visit. Serum and urine pregnancy test will be administered  at Visit 8  for 
patients who are rolling over into the Open-l abel Safety Study. A t Visit 5 and Visit 
8/ET, urine pregnancy tests will be administered. Serum pregnancy testing will be 
performed using blood collected as part of protocol-specified sample; urine pregnancy testing will use a urine dipstick. If the  serum pregnancy test at screening is  positive, the 
patient will not be eligible to participate in the study. If a urine pregnancy test is negative and the associated serum pregnancy test is positive, the patient will be discontinued from the study.  
• Hepatitis screening : Blood samples will be collected at Screening (Visit 1)  from all 
patients in order to perform hepatitis B surface antigen, hepatitis B core antibody IgM, and hepatitis C antibody (immunoglobulin G) testing. Confirmatory testing will be undertaken as needed. Test results will be sent to the study site and must be reviewed before Baseline (Visit 2 /Day 1). Any patient who tests positive for hepatitis B surface 
antigen and/or hepatitis B core antibody IgM or positive hepatitis C antibody with a positive confirmatory hepatitis C RNA result will be excluded from participating in the study. Details regarding sample collection , processing, and shippi[INVESTIGATOR_774673]. 
A central laboratory will be used to evaluate all urine and blood samples, which will be collected, processed, and stored according to the instructions provided in the Laboratory  Manual.  
8.3.5 Vital Signs  
Vital signs (pulse rate, systolic and diastolic blood pressure [BP], body temperature , and body 
weight will be assessed at every visit during the study as specified in the Schedule of Evaluations (Table 1-1). Height  and BMI is assessed at Sc reen (Visit 1) only  and w aist circumference will be 
assessed at Screen (Visit 1) and Visit 8/ET.  
Blood pressure and pulse rate will be measured twice: once after the patient is resting quietly in 
the supi[INVESTIGATOR_143463] 2 minutes in the standing positions. BP may be 
measured either manually or by [CONTACT_143488]. 
Patients should be kept as calm and undisturbed as possible while BP and pulse rate measurements 
are taken (eg, there should  be no talking while the BP is being measured). The same arm and BP 
cuff (appropriate to the arm circumference) should be used for all BP measurements. 
Whenever possible, the patient’s weight should be measured at the same time of day; the patient 
should wear his/her usual indoor clothing without jacket and shoes. For each patient, body weight and height should be determined using the same equipment during the study after ensuring its proper calibration. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 49 8.3.6 Electrocardiograms  
A 12 -lead ECG will be performed as  specified in the Schedule of Evaluations  (Table 1-1).  Each 
ECG assessment will be conducted after the patient has been resting quietly in the supi[INVESTIGATOR_143464] -second epochs from 12- lead ECGs. ECG parameters to be measured i nclude 
HR, QRS, PR, QT, QTcB, QTcF and RR intervals. 
The overall interpretation and determination of the clinical significance of ECG findings using the 
interpretation from the central ECG laboratory will be the responsibility of the Investigator. For eligibility criteria, the values reported on the central ECG interpretation report, not the values that 
are printed on the tracing itself, will be used.  
8.3.7 Columbia –Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS is a clinician -rated instrument that reports the  severity of both suicidal ideation and 
behavior ( Posner, 2011 ). The C-SSRS will be completed by a Sponsor-approved rater. 
 Suicidal ideation is classified on a 5 -item scale:  
1. Wish to be dead  
2. Nonspecific active suicidal thoughts  
3. Active suicidal ideation with any methods [not plan] without intent to act 
4. Active suicidal ideation with some intent to act, without specific plan; and  
5. Active suicidal ideation with specific plan and intent.  
The C -SSRS also captures information about the intensity of ideation, specifically the frequency, 
duration, controllability, deterrents, and reasons for the most severe types of ideation.  
Suicidal behavior categories are:  
• Completed suicide 
• Actual attempt  
• Interrupted attempt  
• Aborted attempt, and 
• Preparatory acts or behavior  
More than [ADDRESS_1063958] recent attempts.  
The C -SSRS w ill be completed at all study visits. At Screening (Visit 1), the C -SSRS will be 
completed for the patient’s lifetime history of suicidal ideation and behavior (“Baseline/Screening” version). At all other visits, the C -SSRS will be completed for suicidal ideation and behavior since 
the previous visit (“Since Last Visit” version). Before the patient leaves the study site, the Investigator or appropriately qualified designee will assess the patient’s C- SSRS results.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063959] obtain appropriate psychiatric consultation. The results of the C -SSRS 
will be recorded in the eCRF . The C -SSRS will be completed by a trained and Sponsor -approved 
rater. 
8.3.8 Extrapyramidal Scales 
[IP_ADDRESS] Abnormal Involuntary Movement Scale (AIMS)  
The AIMS ( Guy 1976) measures facial and oral movements, extremity movements, and trunk 
movements. Seven items are rated on a scale from none (0) to severe (4). A score of “mild” in 2 
or more categories or a score of “moderate” or “severe” in any 1 category results in a posi tive 
AIMS score (ie, the scores are not averaged). Additionally, overall severity is scored on the basis of severity of abnormal movements and incapacitation due to abnormal movements. The patient’s awareness of and distress caused by [CONTACT_143489]. There are an additional 2 items on dental status that are answered yes or no. The AIMS is to be completed at Baseline (Visit 2) and Visits 4, 6 and 8/ET according to Schedule of Ev aluations ( Table 1-1).  
[IP_ADDRESS] Barnes Akathisia Rating Scale (BARS)  
The BARS is a rating scale for drug -induced akathisia developed by [CONTACT_143490] ( Barnes  1989 ). It 
includes the rating of observable restless movements, the subjective awareness of restlessness, and the distress associated with the akathisia. There is also a global rating for severity. The scale is completed by [CONTACT_143491] -based rater after a standard examination. Objective 
akathisia, subjective awareness and subjective distress are rated on a 4 -point scale from 0 to 3, 
yielding a total score from 0 to 9. The Global Clinical Assessment of Akathisia is rated separately, on a 6- point scale from 0 to 5. The BARS is to be completed at Baseline (Visit 2) and Visits 4, 6 
and 8/ET according to Schedule of Ev aluations  (Table 1-1).  
[IP_ADDRESS] Simpson -Angus Scale (SAS)  
The SAS is a measure of extrapyramidal side effects ( Simpson &Angus, 1970). The SAS is used 
for assessment of antipsychotic -induced parkinsonism in both clinical practice and research 
settings. Ten ite ms including rating gait, arm droppi[INVESTIGATOR_007], shoulder shaking, elbow rigidity, wrist 
rigidity, leg pendulousness, head droppi[INVESTIGATOR_007], glabella tap, tremor, and salivation are rated on a scale from 0 (normal) to 4 (extreme in severity). The SAS should be conducted by [CONTACT_143492] -based rater in a room where the patient can walk a sufficient distance to allow a natural 
pace (eg, 15 paces). Each side of the body should be examined. The SAS is to be completed at Baseline (Visit 2) and Visits 4, 6 and 8/ET according to Schedule of Ev aluations ( Table 1-1).  
8.3.9 Modified Physical Examination  
A modified physical examination, excluding genital/rectal examina tions, will be performed at the 
visits specified in the Schedule of Evaluations ( Table 1-1). The examinations will be performed 
by a professionally trained physician or health professional licensed to perform physical examinations.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 53   
   
   
   
   
   
   
   
  
  
  
   
   
   
   
   
  
   
   
  
  
  
   
   
   
   
  
  
 
   
  

Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 54    
  
   
  
  
  
   
   
   
   
   
  
   
   
  
  
  
   
   
   
   
   
  
   
  
  
  
   
   
   

Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 57 9.4 Statistical Analyses 
9.4.1 Patient Disposition  
The number of  patients  in each study population will be summarized by [CONTACT_143493]: 
• The number of patients who were screened will be summarized overall by [CONTACT_91294].  
• The number of patients in the Safety and m ITT populations will be summarized overall 
and by [CONTACT_143494].  
In addition, the number and percentage of patients who completed the Double-blind T reatment 
Period and who prematurely discontinue from the D ouble-blind T reatment Period will be 
summarized overall, by [CONTACT_1570], and by [CONTACT_143495]-blind Treatment Period.  The reasons for premature discontinuation from the Double-blind 
Treatment  period as recorded on the termination page of the eCRF will be summarized (number 
and percentage) by [CONTACT_143496].  
9.4.2 Demographics and Other Baseline Characteristics  
Demographic parameters as allowed by [CONTACT_143483] (eg, age, sex, race, ethnicity, 
weight, body mass index) and other baseline characteristics will be summarized by [CONTACT_774677] m ITT populations. 
Prior medical and surgical history will be summarized by [CONTACT_143496]. 
Baseline efficacy parameters will be summarized by [CONTACT_143498]. 9.4.[ADDRESS_1063960] d ose of double-blind study treatment  
will not be included in the summary but will be included in the patient data listings.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 58 9.4.4 Extent of Exposure and Treatment Compliance 
[IP_ADDRESS] Extent of Exposure 
Exposure to study treatment for the Safety Population will be summarized for treatment duration, 
calculated as the number of days from the date of the first dose of double -blind study treatment 
taken to the date of the last dose taken, inclusive. The number and percentage of patients  with each 
treatment duration of ≥  1 day, ≥ 7 days, etc, will be summarized by [CONTACT_1570], respectively. 
[IP_ADDRESS] Measurement of Treatment Compliance 
Dosing compliance for a specified period is defined as the total number of capsule s of study 
treatment  actually taken by a patient  during th e treatment period divided by [CONTACT_774678] 100. 
The total number of capsules  actually taken duri ng the treatment  period will be calculated from 
the study treatment  record. Descriptive statistics for study treatment  dosing compliance together 
with compliance category will be summarized by [CONTACT_143496]. 
9.4.5 Efficacy Analyses 
The primary efficacy analyses and the sensitivity analysis will be based on the mITT and ITT 
Populations; other efficacy analyses will be based on the ITT Population, unless stated otherwise. The baseline for each specific efficacy endpoint is def ined as the last measurement prior to the 
first dose of randomized treatment. All statistical hypothesis tests will be performed at the 2 -sided 
5% significance level for main effects. All confidence intervals (CIs) will be 2 -sided 95% CIs, 
unless stated ot herwise.  
All investigative sites with fewer than 2 m ITT patients per treatment group will be pooled as  
follows: The largest site with fewer than [ADDRESS_1063961] investigative site  within 
the same country or geographic region, if one exists; otherwise, no further pooling is  needed. Sites 
with the same number of m ITT patients will be ordered in ascending order of their  numerical site 
identification number. This will serve as a tie‐breaker rule in case multiple sites  have the same 
number of m ITT patients. Should the primary efficacy analysis model present  convergence issues, 
after testing the sequence of correlation structures, then the site effect will  be reconsidered and 
may be dropped from the model. These pooled investigative sites, as  determined based on the 
primary efficacy response variable, will be used for any analysis that  has investigative site as a 
fixed effect in the model. The actual investigative site numbers will be included in the listings. For 
analyses that are based on the ITT Population and include site as  a factor, additional pooling will  
be performed starting from the m ITT pooled sites. Sites with patients who are in ITT Population 
but not the m ITT Population will be pooled, using the same algorithm as outlined above.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063962] provide the following to the Sponsor, before the start of the study: 
• A completed and signed Form FDA [ADDRESS_1063963] be completed and returned to the Sponsor. 
• A fully executed contract 
• The curricula vitae for the Investigator and all sub -investigators listed on Form FDA 1572  
or equivalent form, if applicable , including a copy of each physician’s license 
• Financial disclosure agreement completed and signed by [CONTACT_143501]-
investigators listed on Form FDA 1572 or equivalent form, if applicable  
• A copy of the original IRB/IEC approval for conducting the study. If the study is ongoing, 
renewals must be submitted at yearly intervals. All subsequent modifications must be submitted and approved by [CONTACT_1201] 
• A copy of the IRB/IEC- approved ICF  
• A copy of the HIPAA authorization form, or other applicable local privacy forms 
• A list of the IRB/IEC members or the US Department of Health and Human Services general assurance number  
• The Investigator’s Statement page in this protocol signed and dated by [CONTACT_737]. 
10.2.[ADDRESS_1063964] each patient’s use. All unused study treatment  
must be returned to the Sponsor-designated central depot. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 68 10.2.4 Case Report Forms  
All patient data relating to the study, except for data electronically transmitted (eg, central 
laboratory results), will be recorded on eCRFs to be provided by [CONTACT_143502]. The Investigator is re sponsible for verifying that all data entries in the eCRFs are accurate 
and correct by [CONTACT_143503]. The 
Investigator must maintain and retain accurate documentation that supports the information enter ed into the EDC system for source document verification and possible regulatory inspection. 
10.2.[ADDRESS_1063965] of this study, including eCRFs, source documents (eg, medical records, laboratory reports), consent forms, regulatory documents, and medication inventory records must be retained by [CONTACT_13177] a period of at least [ADDRESS_1063966] be notified in writing of the name [CONTACT_153917].  
10.2.6 Patient Confidentiality  
All patient records will be identified by [CONTACT_143504]. Patients’ names are not to be transmitted to the Sponsor. The Investigator will keep a master patient list on which the patient ’s identification number and the full name, address, and telephone number are list ed. 
However, the list will never leave the site and will be archived at the site after the end of the study.
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 69 10.3 Data Quality Assurance 
10.3.1 Data Monitoring 
Before any  patient enters the study, a representative of the Sponsor will meet with the I nvestigator 
and the study center personnel to review the procedures to be followed during the study. Electronic 
data capture (EDC) functionality training is provided via computer -based training to train 
Investigators and authorized designees on recording t he data in the eCRFs using the EDC system.  
The Investigator will maintain complete source documents (eg, signed ICFs, written or electronic medical records, pharmacy records). Source documents provide evidence for the existence of study patients and subst antiate the integrity of the data collected in the eCRF. The Investigator will make 
available to the  Sponsor or  study monitor or designee source documents (written notes and 
electronic medical records, if used), signed ICFs, and all other study- related documents. 
Study monitors or designee, appointed by [CONTACT_1034], will perform ongoing source document verification to confirm that data entered into the eCRF are accurate, complete, and verifiable from source documents; that the safety and rights of patients are protected; and that the study is conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. After the first patient is randomized , the 
study monitor or designee  will periodically monitor the progress of the study by [CONTACT_143505]-
site visits. In addition to on- site source document verification, study monitors will review study 
progress remotely, possibly warranting more frequent communication and/or study center visit s. 
Details of monitoring activities are provided in the Monitoring Plan. 
10.3.[ADDRESS_1063967] access. Patient data are to be entered into the E DC system by [CONTACT_21438]/her 
designee using his/her assigned EDC user account. The Investigator or his/her designee will record 
all patients’ study data in the eCRF, unless the data are transmitted to the Sponsor electronically (eg, laboratory data). Data entered in the eCRF must be consistent with the source documents or the discrepancies must be explained. The Investigator is responsible for verifying that all data entries are accurate and correct. The Investigator may need to request previous  or external medical 
records to support study data. 
The Sponsor is responsible for the data management of this study, including quality checking of 
the data. The Sponsor or designee will review study data for completeness, logic, and protocol adherence, us ing a combination of manual review and programmatic edit checks. After data entry 
into the EDC system by [CONTACT_18370], a combination of manual and programmatic edit checks will be used to review the data for completeness, logic, and adherence to study protocol. As a result of these edit checks, data monitoring, and reviews, queries may be 
electronically issued to the study center and should be answered electronically via the EDC system. Each query will carry identifying information (assigned username, date, and time) to assist the 
Sponsor and the Investigator on the origin of the data clarification request and the response provided by [CONTACT_737]. All data changes made to the patient’s data via a data query will be approved by [CONTACT_143506]. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063968] as to guarantee patient confidentiality in accordance with the legal stipulations applying to confidentiality of data. Study records (eg, copi[INVESTIGATOR_1495], laboratory 
reports, and regulatory documents) will be retained at the study center, along with adequate source documentation, according to FDA and ICH requirements. All study records must be available for 
inspection by [CONTACT_1034], its authorized representatives, the FDA, or other health authorities. 
Source documents will be used at the study centers and may include a patient’s medical record, 
hospi[INVESTIGATOR_1332], clinic charts, the Investigator’s patient study files, as well as the results of diagnostic tests such as laboratory tests, ECGs, etc. A  centralized clinical laboratory will be used 
for the analysis of all blood samples. Additional information on the collection and handling of samples is detailed in the Laboratory Manual. 
10.[ADDRESS_1063969] include the following items:  
• A statement that the study involves research and an explanation of the purposes of the research; a description of the procedures to be followed and the identification of any procedures that are experimental; and the expected duration of the patient’s participation 
• A description of any reasonably foreseeable risks or discomforts to the patient 
• A description of any benefits to the patient or to others that may reasonably be expected from the research. If the patient is to be paid for participating in the study, the consent form must state the amount that he/she  will receive and the schedule of payment (to ensure 
neither coercion nor undue influence). 
• A disclosure of appropriate alternative procedures or courses of treatment, if any, that 
might be advantageous to the patient. 
• A statement describing the extent, if  any, to which confidentiality of records identifying 
the patient will be maintained and noting the possibility that the FDA  or other local health 
authority, the Sponsor, the IRB/IEC, or an authorized contract research organization may 
inspect the records 
• For research involving more than minimal risk, an explanation of whether any medical treatment is available if injury occurs and, if so, what it consists of or where further information may be obtained 
• An explanation of whom to contact, including the relevant telephone number, for answers to pertinent questions about the research and the research patient’s rights and whom to contact [CONTACT_44751] a research -related injury to the patient. (Note: In some cases, it may 
be necessary to identify a person other  than the Investigator as the contact. The guidance 
of the IRB/IEC may be required.) 
• For EU countries, the ICF will include a statement of whom to contact, including relevant phone and email address, for questions about patient data confidentiality or data  breach’ 
per GDPR.  
• A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject/patient is otherwise entitled, and that the patient may discontinue participation at any time witho ut penalty or loss of benefits to 
which the patient is otherwise entitled  
• A statement that the treatment or procedures may involve risks to the patient (or to the embryo or fetus if the patient is, or may become, pregnant) that are at present unforeseeable  
• The expected circumstances for which the patient’s participation may be terminated by [CONTACT_143507]’s consent 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 72 • Any additional costs to the patient that may result from participation in the research  
• The consequences of a pat ient’s decision to withdraw from the research and procedures for 
an orderly termination of the patient’s participation  
• A statement that significant new findings developed during the course of the research that 
may relate to the patient’s willingness to continue participation will be provided to the patient  
• The approximate number of patients involved in the study 
• A statement of permission, providing consent for the patient  to participate (eg, “I agree to 
participate . . .”) 
• A place for the patient’s signatur e and date of signing of the ICF  
• A statement indicating that information about this study has been, or will be, entered into a databank that is publicly accessible at www.ClinicalTrials.gov.  
• A copy of the signed consent form must be given to the patient.  
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 73 12 REFERENCES  
Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989.154:672-6. 
CAPLYTA® US Prescribing Information: caplyta_pi.pdf (intracellulartherapi[INVESTIGATOR_014].com) . 
December  2019. 
Chandler, GM, Iosifescu, DV, Pollack, MH, et al. Validation of the [LOCATION_005] General 
Hospi[INVESTIGATOR_143465] (ATRQ) . CNS Neurosci Ther . 2010; 
16:322-325. 
Food and Drug Administration. ( June 2018). Major Depressive Disorder: Developi[INVESTIGATOR_143466] . Available: https://www.fda.gov/media/113988/download 
Food and Drug Administration. ( May 2021). E9(R1) S tatistical Principles for Clinical Trials: 
Addendum: Estimands and Sensitivity Analysis in Clinical Trials . Available: 
https://www.fda.gov/media/148473/download Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department 
of Health Education, and Welfare; 1976. 
Keller A, McGarvey EL, and Clayton AH. Reliability and construct  validity of the Changes in 
Sexual Functioning Questionnaire short- form (CSFQ -14). J Sex Marital Ther . 2006;32: 43-52 
Kupferber g A, Bicks L, Hasler G. Social functioning in major depressive disorder. Neurosci 
Biobehav R. 2016; 69: 313-332. Little, A . Treatment -resistant depression. Am Fam Phys. 2009; 80(2): 167-172. 
Lu K. Sample size calculations with multiplicity adjustment for longitudinal clinical trials  with 
missing data. Stat Med. 2012; 31:19-28. Lu K, Mehrotra DV. Specification of covariance structure in longitudinal data analysis for 
randomized clinical trials. Stat Med. 2010; 29:474-488. 
Montgomery SA and Åsberg M. A new depression scale designed to be sensitive to change. Br J 
Psychiatry. 1979; 134:382-389. 
Posner K, Brown GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: initial 
validity and internal consistency findings from three multisite studies with adolescents and adults. 
Am J Psychiatry. 2011;168(12):1266-77.  
Rush A, Trivedi MH , Wisniewski SR, et al. Acute and longer -term outcomes in depressed 
outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006: 
163: 1905-1917. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-502 
Adjunctive MDD Study  2 18 Aug 2021 
Confidential         Page 74 Rush, A, Trivedi, MH, Ibrahim, HM, et al. The 16- item Quick Inventory of Depressive 
Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric 
evaluation in patients with chronic major depression. Biol Psychiatry , 2010; 54(5): 573-583.  
Sheehan DV, Lecrubier Y, Harnett -Sheehan K, Amorim P, et al. The Mini International 
Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998; 59 (suppl 20):22-33.  
Simpson GM. Angus  JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 
Suppl. 1970; 212:11–9. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) 
treatment for depression: A STAR*D report. Am J Psychiatry. 2007: 164:1189-1197. 
Intra-Cellular Therapi[INVESTIGATOR_014], Inc.  Protocol ITI -007-[ADDRESS_1063970] the study in accordance with Amendment 1 to the  Original Protocol for Study 
ITI-007-502, dated 18 Aug 2021, and with all applicable government regulations and GCP 
guidance, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal and/or local regulations and ICH guidelines. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without prior authorization from Intra- Cellular Therapi[INVESTIGATOR_014], Inc.  
_____________________________________ _____________________ 
Principal Investigator [INVESTIGATOR_774674]  
_____________________________________  ______________________ Principal Investigator [CONTACT_5627] (printed)    Site Number  